AKT1 and breast carcinoma: Additionally, another clinical trial investigating MK-2206 in patients with advanced breast cancer, specifically those with PIK3CA or AKT mutations, and/or PTEN mutations or loss, showed a minimal antitumor response (NCT01277757) [344].